Our understanding of mechanisms in the tumour microenvironment is increasing year-on-year. Over the past years, the industry has come to realize that relying on checkpoint blockade mechanisms and monotherapy approaches are not enough to overcome the immunosuppressive
nature of the tumour microenvironment. This meeting will explore current understanding of immune tolerance and approaches to overcome immune resistance, at the same time highlight strategies to modulate the tumor microenvironment through various activators
and inhibitors of immune responses to improve targeting and tumor-specificity, or enhance potency and safety.